Latham & Watkins Advises Cheplapharm on Acquisition of Gemzar®

Latham & Watkins LLP has advised Cheplapharm Group, the global market leader in acquiring established originator products from research-based pharmaceutical companies, on the acquisition of the worldwide marketing rights (excluding South Korea) for Gemzar® with the active ingredient gemcitabine from Eli Lilly and Company. The product is part of the treatment regimen for various types of cancer. Closing of the transaction is subject to the fulfilment of customary closing conditions.

Cheplapharm was supported in-house by the following legal team:

Jan Klumb (Senior Director Legal Cheplapharm Arzneimittel GmbH), Anne Noltin (Team Lead M&A), Felix Kobel (Senior Director Legal Cheplapharm Schweiz GmbH), and Anees Ahmed (Legal Counsel).

The Latham team was led by Hamburg Healthcare & Life Sciences partner Christoph Engeler, with associates Henrietta Ditzen and Antanas Grimalauskas. Advice was also provided on intellectual property matters by Frankfurt partner Susan Kempe-Müller, with associates Daniela Jaeger and Johannes Huschka; on data privacy matters by Frankfurt counsel Wolf-Tassilo Böhm, with associate Clemens Ganz; and on tax matters by Hamburg partner Tobias Klass.